Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.

ABSTRACT:

SUBMITTER: Black GS 

PROVIDER: S-EPMC9335504 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature